Paired Immunoglobulin-like Receptor (PIR)-A Is Involved in Activating Mast Cells through Its Association with Fc Receptor γ Chain by Maeda, Akito et al.
 
991
 
J. Exp. Med. 
 
Ó
 
 
 
The Rockefeller University Press • 0022-1007/98/09/991/05 $2.00
Volume 188, Number 5, September 7, 1998 991–995
http://www.jem.org
 
Brief Deﬁnitive Report
 
Paired Immunoglobulin-like Receptor (PIR)-A
Is Involved in Activating Mast Cells through
Its Association with Fc Receptor 
 
g
 
 Chain
 
By Akito Maeda, Mari Kurosaki, and Tomohiro Kurosaki
 
From the Department of Molecular Genetics, Institute for Liver Research, Kansai Medical University, 
Moriguchi 570-8506, Japan
 
Summary
 
Paired immunoglobulin-like receptor (PIR)-A and PIR-B possess similar ectodomains with six
immunoglobulin-like loops, but have distinct transmembrane and cytoplasmic domains. PIR-B
bears immunoreceptor tyrosine-based inhibitory motif (ITIM) sequences in its cytoplasmic do-
main that recruit Src homology (SH)2 domain–containing tyrosine phosphatases SHP-1 and
SHP-2, leading to inhibition of B and mast cell activation. In contrast, the PIR-A protein has a
charged Arg residue in its transmembrane region and a short cytoplasmic domain that lacks
ITIM sequences. Here we show that Fc receptor 
 
g
 
 chain, containing an immunoreceptor ty-
rosine-based activation motif (ITAM), associates with PIR-A. Cross-linking of this PIR-A
complex results in mast cell activation such as calcium mobilization in an ITAM-dependent
manner. Thus, our data provide evidence for the existence of two opposite signaling pathways
upon PIR aggregation. PIR-A induces the stimulatory signal by using ITAM in the associated
 
g
 
 chain, whereas PIR-B mediates the inhibitory signal through its ITIMs.
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ross-linking of immune receptors such as BCR,
TCR, or FcR on a variety of cells leads to their acti-
vation through the sequential activation of protein tyrosine
kinases (PTKs) (1–3). Several features have emerged that
are common to these activating receptors. They are all oli-
gomeric complexes in which ligand binding and signal
transduction are compartmentalized into distinct receptor
subunits. Hence, these receptors comprise one or more im-
munoreceptor tyrosine-based activation motif (ITAM)-
containing subunits. When the ligand-binding subunit(s) of
the receptor is engaged, the cytoplasmic ITAMs are ty-
rosine phosphorylated by src-family PTKs. This leads to
the recruitment of syk-family PTKs, which trigger a cas-
cade of intracellular phosphorylations that result in cellular
activation.
Balancing these activation responses are the inhibitory
receptors and their associated signaling molecules, which
are responsible for setting threshold levels for activation sig-
nals as well as terminating activation responses. These in-
hibitory receptors also share several common features.
They have one or more immunoreceptor tyrosine-based
inhibitory motifs (ITIMs) in their cytoplasmic domains, ty-
rosine phosphorylation of which leads to the recruitment of
signaling molecules capable of inhibiting cell activation (4–
7). Indeed, NK inhibitory receptors recruit tyrosine phos-
phatase SHP-1 to inhibit NK cell activation (8–10). Cer-
tain isoforms of NK receptors that lack ITIM sequences
have been proposed to function as activation receptors
rather than inhibitory receptors (11). A conspicuous feature
of these noninhibitory NK receptors is the presence of a
basic amino acid in the transmembrane domain, which may
allow their association with signal-transducing proteins
such as DAP12, as demonstrated recently for killer-activat-
ing receptors (12, 13).
The paired Ig-like receptors (PIRs) recently identified
on B cells and myeloid lineage cells include PIR-A mole-
cule, which has a short cytoplasmic domain, and PIR-B
molecule, which bears four potential ITIMs in its cytoplas-
mic domain (14, 15). In contrast to the unique transmem-
brane and cytoplasmic domains between PIR-A and PIR-B,
extracellular regions of these molecules are very homolo-
gous, suggesting that both molecules bind the putative
common ligand. We and others have recently demon-
strated that PIR-B functions as an inhibitory receptor in B
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and mast cells (16, 17). Here, we show that PIR-A func-
tions as an activation receptor as a consequence of its asso-
ciation with the ITAM-bearing FcR
 
g
 
 chain in mast cells.
 
Materials and Methods
 
Cells, Expression Constructs, and Abs.
 
Chicken DT40 cells and
mouse A20 IIA1.6 cells (Fc
 
g
 
RII-negative A20 derivative) were
maintained in RPMI 1640 supplemented with 10% FCS, penicil-
lin, streptomycin, glutamine, and 50 
 
m
 
M 2-ME. RBL-2H3 cells
(provided by N. Yamamoto and T. Yasuda, Bayer
 
 
 
Yakuhin, Ltd.,
Kyoto, Japan) and 293 T cells were cultured in MEM and
DMEM, respectively, instead of RPMI 1640. Fc
 
g
 
RIII–PIR-A
chimera, mutated FcR
 
g
 
 chain (18), and hemagglutinin (HA)-
tagged PIR-A were created by the PCR method and subcloned
into the pApuro (19), pAneo (20), and pApuro (19) vectors, re-
spectively. Fc
 
g
 
RIII–PIR-A chimera contains the extracellular
domain of human Fc
 
g
 
RIIIA
 
a
 
 (21) attached directly to the trans-
membrane and cytoplasmic regions of PIR-A (15). Resulting
constructs were confirmed by DNA sequencing. These expres-
sion constructs were transfected into DT40, A20 IIA1.6, and
RBL-2H3 cells by electroporation, and selected in the presence
of puromycin (0.5 
 
m
 
g/ml) or G418 (2 mg/ml). Cell surface ex-
pression levels of Fc
 
g
 
RIII–PIR-A were checked by flow cyto-
metric analysis using anti–human Fc
 
g
 
RIII mAb, 3G8 (22), and
expression level of FcR
 
g
 
 chain was analyzed by Western blotting
using anti-
 
g
 
 chain Ab (23). The calcium phosphate precipitation
method was used for transfection into 293 T cells. Biotin-tagged
3G8 mAb, streptavidin, antiphosphotyrosine mAb (4G10), F(ab
 
9
 
)
 
2
 
rabbit anti–mouse IgG, and anti-HA epitope mAb were purchased
from PharMingen (San Diego, CA), Vector Labs. (Burlingame,
CA), Upstate Biotechnology, Inc. (Lake Placid, NY), Chemicon
International, Inc. (Temecula, CA), and Boehringer Mannheim
(Tokyo, Japan), respectively.
 
Immunoprecipitation and Western Blotting Analysis.
 
To detect as-
sociation of 
 
g
 
 chain with Fc
 
g
 
RIII–PIR-A, cells were solubilized
in 1% digitonin buffer (1% digitonin, 0.12% Triton X-100, 150
mM NaCl, and 20 mM triethanolamine, pH 7.8). Cell lysates
were sequentially incubated with mAb 3G8 or anti-HA mAb,
and then with anti–mouse IgG agarose. For detection of tyrosine
phosphorylation of 
 
g
 
 chain, stimulated cells were solubilized in
1% NP-40 buffer (1% NP-40, 150 mM NaCl, 1 mM EDTA, and
20 mM Tris, pH 7.5). Cell lysates were sequentially incubated
with anti–
 
g
 
 chain Ab and protein A agarose. Protease inhibitors
and phosphatase inhibitors were added to both digitonin and NP-
40 buffer as previously described (20). Immunoprecipitates were
separated by SDS-PAGE gel, transferred to nitrocellulose mem-
brane, and detected by appropriate Abs and ECL system (Amer-
sham Pharmacia Biotech, Piscataway, NJ).
 
Northern Analysis.
 
RNA was prepared from A20 IIA1.6 and
RBL-2H3 cells using the guanidium thiocyanate method. Total
RNA (20 
 
m
 
g) was separated in a 1.2% formaldehyde gel, trans-
ferred to Hybond-N
 
1
 
 nylon membrane (Amersham Pharmacia
Biotech), and probed with 
 
32
 
P-labeled FcR
 
g
 
 chain cDNA.
Figure 1. FcgRIII–PIR-A induces calcium mobilization and associates
with FcRg chain in RBL-2H3 cells. (A) Calcium mobilization by cross-
linking of FcgRIII–PIR-A. Left arrows indicate application of 3G8 or bi-
otin-tagged 3G8, and right arrows indicate application of F(ab9)2 anti–
mouse IgG or streptavidin in RBL-2H3 or A20 IIA1.6 cells, respectively.
Surface expression levels of FcgRIII–PIR-A are indicated in inset boxes.
The x and y axes for the histograms indicate fluorescence intensity (log
scales) and relative cell number, respectively. (B) Northern blot analysis
using mouse g cDNA as a probe. Bottom panel shows 28S and 18S ribo-
somal RNA pattern. (C) Association of FcgRIII–PIR-A with g in RBL-
2H3 cells. Immunoprecipitates with 3G8 were separated by 15% SDS-
PAGE gel and detected by anti-g Ab.
Figure 2. Association of FcgRIII–PIR-A
with g chain in 293 T cells. (A) FACSÒ
(Becton Dickinson, San Jose, CA) analysis of
293 T cells transiently expressing FcgRIII–
PIR-A in the presence or absence of g.
Cells were labeled with FITC-conjugated
3G8. Nontransfected 293 T cells were used
as a negative control. (B) Association was
detected as described in legend to Fig. 1. In
the case of association of HA-tagged PIR-A
with g, anti-HA mAb was used for immuno-
precipitation instead of 3G8. 
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Calcium Measurements.
 
Cells (5 
 
3 
 
10
 
6
 
) were suspended in
PBS containing 20 mM Hepes (pH 7.2), 5 mM glucose, 0.025%
BSA, and 1 mM CaCl
 
2
 
, and loaded with 3 
 
m
 
M Fura-2/AM at
37
 
8
 
C for 45 min. Cells were washed twice and adjusted to 10
 
6
 
cells/ml. Continuous monitoring of fluorescence from the cell
suspension was performed using Hitachi F-2000 fluorescence
spectrophotometer (Hitachi Limited, Tokyo, Japan) at an excita-
tion wavelength of 340 nm and an emission wavelength of 510 nm.
Calibration and calculation of calcium levels were done as previ-
ously described (24). Fc
 
g
 
RIII–PIR-A on RBL-2H3 and DT40
cells was stimulated with anti-Fc
 
g
 
RIII mAb (3G8, 10 
 
m
 
g/ml)
and was subsequently cross-linked with F(ab
 
9
 
)
 
2
 
 anti–mouse IgG
(25 
 
m
 
g/ml). Biotin-tagged 3G8 (10 
 
m
 
g/ml) and streptavidin (25
 
m
 
g/ml) were used for stimulation of Fc
 
g
 
RIII–PIR-A on A20
IIA1.6 cells.
 
Results and Discussion
 
PIR-A Is Capable of Activating Mast Cells.
 
Structural fea-
tures of PIR-A have prompted us to test whether PIR-A is
able to transmit activation signals. For this purpose, a chi-
meric molecule with the transmembrane and cytoplasmic
domains of PIR-A and the extracellular domain of human
Fc
 
g
 
RIII was constructed (Fc
 
g
 
RIII–PIR-A), and transfected
into mouse A20 IIA1.6 B cells and rat RBL-2H3 basophilic
leukemia cells in order to obtain transformants. Expression
level of this chimeric receptor was assessed by flow cyto-
metric analysis using anti–human Fc
 
g
 
RIII mAb, 3G8 (Fig.
1 
 
A
 
,
 
 insets
 
). As shown in Fig. 1 
 
A
 
, stimulation of Fc
 
g
 
RIII–
PIR-A chimeric receptor on RBL-2H3 cells with 3G8 and
subsequent cross-linking resulted in a transient rise in
[Ca
 
2
 
1
 
]
 
i
 
, whereas this [Ca
 
2
 
1
 
]
 
i
 
 increase could not be detected
in the A20 IIA1.6 transformant expressing Fc
 
g
 
RIII–PIR-
A, demonstrating that Fc
 
g
 
RIII–PIR-A is able to evoke the
activation signal only in RBL-2H3 cells. Thus, these data
suggest that Fc
 
g
 
RIII–PIR-A is not capable of transmitting
the activation signal by itself and that the responsible mole-
cule(s) for the activation signal is expressed in RBL-2H3
cell but not in A20 IIA1.6 cells. One such candidate is the
FcR
 
g
 
 chain, which is one component of the Fc
 
g
 
RIII and
Fc
 
e
 
RI complexes in mast cells (25). Indeed, the 
 
g
 
 chain is
expressed in RBL-2H3 cells but not A20 IIA1.6 cells, as
revealed by Northern (Fig. 1 
 
B
 
) and Western blotting anal-
ysis (data not shown).
 
FcR
 
g
 
 Chain Associates with Fc
 
g
 
RIII–PIR-A.
 
To demon-
strate that 
 
g
 
 chain is associated with Fc
 
g
 
RIII–PIR-A,
RBL-2H3 cells expressing this chimeric receptor were lysed
by digitonin buffer, followed by immunoprecipitation with
3G8. The immune complexes were separated by SDS-
PAGE gel and blotted with anti-
 
g
 
 chain Ab, demonstrating
the association of 
 
g
 
 chain with Fc
 
g
 
RIII–PIR-A in RBL-
2H3 cells (Fig. 1 
 
C
 
). This association was also shown by
transfection experiments using 293 T cells. Fc
 
g
 
RIII–PIR-A
by itself can be expressed on the cell surface of 293 T cells
to some extent, whereas cotransfection of 
 
g
 
 with Fc
 
g
 
RIII–
PIR-A enhanced cell surface expression of this chimeric
receptor (Fig. 2 
 
A
 
), suggesting that 
 
g
 
 chain is involved in
transport of Fc
 
g
 
RIII–PIR-A to cell surface in 293 T cells.
Moreover, the interaction of 
 
g
 
 chain with Fc
 
gRIII–PIR-A
was reconstituted in 293 T cells, as demonstrated by coim-
munoprecipitation experiments using digitonin buffer (Fig.
Figure 3. Expression of FcgRIII–PIR-A
and g in DT40 transformants. (A) FACSÒ
analysis of DT40 cells by using FITC-con-
jugated 3G8. Parental DT40 cells were used
as a negative control. (B) Expression of g by
Western blot analysis using anti-g Ab.
Transformant cells were directly dissolved in
SDS-sample buffer.
Figure 4. The FcgRIII–PIR-A complex transmits activation signals in
the presence of g. (A) Calcium mobilization by cross-linking of FcgRIII–
PIR-A. Transformants shown in Fig. 3 were stimulated by 3G8 (left ar-
rows) and F(ab9)2 anti–mouse IgG (right arrows). (B) Tyrosine phosphoryla-
tion of g by cross-linking of FcgRIII–PIR-A. Transformant cells were
stimulated with 3G8 (3 min), and then F(ab9)2 anti–mouse IgG (3 min).
Cells were dissolved by NP-40 buffer, immunoprecipitated by anti-g Ab,
separated by 15% SDS-PAGE gel, and probed with antiphosphotyrosine
mAb 4G10. Membrane was reprobed with anti-g Ab (bottom).994 Association of PIR-A with FcRg Chain
2 B). This association was also observed by cotransfection
of g with HA-tagged PIR-A (Fig. 2 B), indicating that na-
tive PIR-A can be associated with FcRg chain.
FcRg Chain Is Involved in Transmitting Activation Signals
through FcgRIII–PIR-A Complex by ITAM-dependent Mecha-
nism. To show that the association of g chain with FcgRIII–
PIR-A is critical for transmitting activation signals, we used
the DT40 B cell system, since this cell line does not express
g chain like A20 cells. After obtaining DT40 transformant
expressing FcgRIII–PIR-A (Fig. 3 A), we transfected
wild-type  g chain or mutated g chain into this DT40 trans-
formant using another drug selection marker to isolate
DT40 cells expressing both FcgRIII–PIR-A and g chain.
Mutation of the g chain (Tyr65 and Tyr76 to Phe) was de-
signed to test whether the activation signal is dependent on
the ITAM sequence located in the cytoplasmic domain of
g chain. Expression level of g chain was assessed by West-
ern blotting analysis with anti–g chain Ab, and clones ex-
pressing comparable levels of wild-type g and mutated g
were selected (Fig. 3 B) and analyzed. Although FcgRIII–
PIR-A alone was expressed on the cell surface of DT40 B
cells, introduction of either wild-type g chain or mutated g
chain enhanced the level of cell surface expression of the
chimeric receptor about fivefold, as demonstrated by flow
cytometric analysis (Fig. 3 A). These observations strengthen
our previous conclusion that g chain contributes to cell
surface expression of FcgRIII–PIR-A. However, this g
chain function does not require phosphorylation of ty-
rosine residues in its ITAM sequence.
Stimulation of FcgRIII–PIR-A complex with wild-type
g chain evoked calcium mobilization upon receptor en-
gagement, whereas this [Ca21]i increase could not be de-
tected in DT40 cells expressing FcgRIII–PIR-A alone nor
in the receptor with mutated g chain (Fig. 4 A), indicating
that ITAM of g chain is essential for transmitting the acti-
vation signal. This conclusion was supported further by the
observation that g chain, but not mutated g chain, is ty-
rosine phosphorylated by FcgRIII–PIR-A stimulation (Fig.
4 B). Taken together, our results demonstrate that FcgRIII–
PIR-A is complexed with FcRg chain, the presence of
which is essential for transmitting activation signals.
Coexistence of both activation and inhibitory pathways
upon receptor aggregation allows immune cells to generate
graded responses under different ligand conditions. Assum-
ing that PIR-A and PIR-B recognize the same ligand, the
data presented here together with previous observations
(16, 17), support the model that cell surface receptors with
same or related ligand-binding specificity transmit both ac-
tivation and inhibitory signals through ITAM and ITIM
sequences, respectively (26). Reminiscent of this type of
regulation is Fc receptors; FcgRIIIA transmits the activa-
tion signal, whereas FcgRIIB inhibits the ITAM-induced
activation signal despite the same ligand specificity between
these two receptors (25).
FcRg chain is physically and functionally associated with
FcgRIII–PIR-A. Since the g chain has a very short extra-
cellular domain (18), this association is presumably medi-
ated by transmembrane–transmembrane interactions. Sup-
porting this notion, the transmembrane region of another g
chain–interacting receptor, FcaR, is very similar to that of
PIR-A in that positively charged Arg residue is located in
the same position, although their extracellular and cytoplas-
mic domains are divergent (27). Given the evidence that
HA-tagged PIR-A is also associated with g chain (Fig. 2
B), our data strongly suggest that native PIR-A associates
with FcRg chain in mast cells.
Functional interaction was demonstrated by requirement
of g chain in FcgRIII–PIR-A-induced calcium mobiliza-
tion. More importantly, ITAM of the g chain was tyrosine
phosphorylated upon receptor aggregation (Fig. 4 B), indi-
cating that the PIR-A complex transmits the activation sig-
nal through an ITAM-dependent mechanism. Thus,
PIR-A uses src- and syk-family PTKs to transmit the posi-
tive signal, in a similar manner to the situation with other
ITAM-bearing receptors such as TCR, BCR, or FcRs,
whereas PIR-B mediates the negative signal through re-
cruitment of SHP-1 and SHP-2 to phosphorylated ITIMs
in its cytoplasmic domain.
Both PIR-A and PIR-B appear to be expressed in B
cells and myeloid lineage cells, as assessed by reverse tran-
scriptase PCR (15). The RNA content of PIR-A and PIR-B
may not necessarily reflect the cell surface expression of
each molecule, because associated molecules such as g
chain may enhance the transport of PIR-A to cell surface,
as seen in this study. Since the relative expression level of
PIR-A and PIR-B on cell surface is one of the critical de-
terminants for stimulatory or inhibitory responses, associ-
ated chains such as g participate in PIR functions by not
only conferring the stimulatory capability on PIR-A but
also promoting its cell surface expression.
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Note added in proof. The results that PIR-A is able to transmit a stimulatory signal have been obtained inde-
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